MARKHAM, Ontario, May 15, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a "Common Share") for the month of May 2024, representing $0.936 per Common Share on an annualized basis.
The dividend will be payable on June 14, 2024 to shareholders of record as at May 31, 2024.
The Company's dividends are designated as eligible dividends for Canadian tax purposes in accordance with subsection 89(14) of the Income Tax Act (Canada), and any applicable corresponding provincial and territorial legislation.
About Sienna Senior Living
Sienna Senior Living Inc. (TSX:SIA) offers a full range of senior living options, including independent living, assisted living and memory care under its Aspira retirement brand, long-term care, and specialized programs and services. Sienna's approximately 12,000 employees are passionate about cultivating happiness in daily life. For more information, please visit www.siennaliving.ca.
For further information, please contact: David Hung Chief Financial Officer & Executive Vice President (905) 489-0258 [email protected]
Latest data of InnoCare's (HKEX: 09969; SSE: 688428) orelabrutinib were presented at the European Society for Medical Oncology (ESMO) Congress 2024.
Oral Presentation
A Prospective Study of Orelabrutinib plus Obinutuzumab (O2) in Treatment-naïve...
The global needle holder market is forecasted to grow from USD 367.3 million in 2024 to USD 530.3 million by 2029, reflecting a CAGR of 7.6%. This growth is driven by increased investments in healthcare, a rise in surgeries including microsurgeries...
The National Eczema Association (NEA) today announced the publication of its real-world research identifying patient-reported attributes associated with an atopic dermatitis (eczema) 'flare' to develop a patient-centered, consensus-based working...
Results from the DESTINY-Breast12 phase 3b/4 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated substantial overall and intracranial clinical activity in a large cohort of patients with HER2 positive metastatic breast cancer who have...
Agenus Inc. ("Agenus") , a leader in developing novel immunological agents to treat various cancers, presented data today at the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain. The data from a Phase 1 study of...
Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial clinical activity in a large cohort of patients with HER2-positive metastatic breast cancer...
